Please login to the form below
myelofibrosis
This page shows the latest myelofibrosis news and features for those working in and with pharma, biotech and healthcare.
Celgene to launch five new products through to 2020
myelofibrosis, thalassaemia therapy luspatercept, and CAR-T candidates lisocabtagene maraleucel (liso-cel) for lymphoma and bb2121 for multiple myeloma.
Latest news
-
Geron poleaxed as partner J&J abandons only pipeline drug
of imetelstat in relapsed/refractory myelofibrosis (MF).
-
Daily Brief: Brexit reshuffle brings new health minister, Celgene thalassemia success, Wellcome ready to leap into future
The companies are also developing luspatercept for the treatment of myelofibrosis.
-
CTI slumps as Servier-partnered lymphoma drug fails
After major setback CTI, has promising myelofibrosis candidate to fall back on. ... If approved, it will compete with Incyte and Novartis' Jakafi (ruxolitinib) in myelofibrosis, which is predicted to knock on the door of $1.5bn in sales this year on the
-
Another R&D flop for Incyte, but Jakafi keeps delivering
Jakafi is marketed by Incyte in the US and by Novartis (as Jakavi) in other markets, for polycythemia vera and myelofibrosis. ... after a less-than-optimal FDA approval, and data suggesting that myelofibrosis patients treated with Jakafi may be at
-
Daily Brief
Another drug price sampled was Novartis’ myelofibrosis treatment Jakavi. The algorithm judges that a fair price would be $17, 251 per treatment, far below the UK ($59, 760) and US ($90,
More from news
Approximately 7 fully matching, plus 35 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
The headline value contains significant sales milestones linked to performance of Impact's lead phase III stage asset fedratinib, an oral JAK2 kinase inhibitor in development for the treatment of myelofibrosis ... Acquisition company - remaining 90%. 9
-
Pharma deals in August 2015
Acquisition ‐ company. 1300. Promedior. BMS. PRM 151 recombinant pentraxin‐2 protein for idiopathic pulmonary fibrosis and myelofibrosis.
-
Pharma deals during November 2014
Good news at last. Days after finally getting the FDA's go-ahead to resume development of its lead candidate, imetelsta, for myelofibrosis and myelodysplastic syndrome, Geron has signed a deal
-
NICE and ‘ultra orphans’
It won't, for example, affect medicines such as Novartis' treatment for myelofibrosis, a rare blood cancer of which there are only around 0.4 cases of the condition per 100,
-
Pharma deals during November 2013
patients with myelofibrosis and has activity against genetic mutations linked to myelofibrosis, leukaemia and certain solid tumours.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Boston Biomedical appoints commercial head
At Incyte, she established the company's commercial operations and successfully launched Jakafi (ruxolitinib) for myelofibrosis as part of a collaboration with Novartis.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
THE OTHER SIDE OF...BLOOD CANCER
Meet Sophie. What she suffers from you have probably never heard of: a blood cancer, or neoplasm, called myelofibrosis.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Digital Account Director
-
Salary TBC
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Account Director, Medical Education
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Senior Medical Writer
-
Up to £50, 000 with Benefits
-
Senior Medical Writer
-
Great salary and benefits
-
Project Manager/ Account Manager
-
Salary TBC
Subscribe to our email news alerts
- Drug launches to watch in 2019
- Welcome to the Communique Awards - Communiqué Awards 2018
- ‘Inflexible’ NICE blocking access to rare disease drugs
- GW Pharma's cannabis-based medicine to be tested in dementia
- Immuno-oncology in 2019: the rapid evolution continues
- 2019: CRISPR and therapeutic gene editing comes of age
- BioMarin prepares for haemophilia A gene therapy data readout, filing
- Innovent gears up for PD-1 inhibitor launch in China
- NICE knocks back BioMarin’s Batten disease drug
- Amgen, Servier start second phase 3 trial of heart failure hope
- The importance of co-creation with patients
- McCann Health's next challenge: creative differentiation
PMHub
Complete HealthVizion
Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...
Latest intelligence
- The importance of co-creation with patients
- Overcoming the barriers...
- Three billboards on the road to multichannel
- Chris Ross examines the trends driving multichannel communication in 2019...
- How Medisafe is using AI to improve patient adherence
- Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Quick links
Infographics
